Lilly Foundayo shows weight loss across pre-, peri- and post‑menopause

Study population and headline

Post‑hoc analyses of more than 1,500 female participants from the ATTAIN‑1 and ATTAIN‑2 Phase‑3 trials showed that Foundayo (orforglipron) at the highest randomized maintenance dose (17.2 mg) was associated with significant body‑weight reductions at 72 weeks across pre‑, peri‑ and post‑menopausal women.

ATTAIN‑1 (no diabetes)

In ATTAIN‑1 (n by stage: pre 171, peri 142, post 152), mean weight changes on 17.2 mg at 72 weeks were −12.8% (−28.0 lb), −14.4% (−30.4 lb) and −14.1% (−28.2 lb), respectively. Percentages achieving weight‑loss thresholds reached 80.3–82.7% for ≥5%, 61.5–64.2% for ≥10%, and 40.9–51.5% for ≥15%. Waist circumference reductions reached up to 4.9 in (12.5 cm).

ATTAIN‑2 (with type 2 diabetes)

In ATTAIN‑2 (pre n=10, peri n=33, post n=109), mean weight changes on 17.2 mg at 72 weeks were −11.3% (−23.4 lb), −8.9% (−18.5 lb) and −13.6% (−27.8 lb), respectively. Achievement of ≥15% weight loss ranged up to 44.2%, and waist circumference fell up to 4.3 in (11.0 cm).

Drug and trial context

Foundayo is a once‑daily, oral non‑peptide GLP‑1 receptor agonist that can be taken any time of day without food or water restrictions and is FDA‑approved for chronic weight management in adults with obesity or certain adults with overweight. ATTAIN‑1 and ATTAIN‑2 were 72‑week, randomized, double‑blind, placebo‑controlled Phase‑3 trials; reported results refer to the highest maintenance dose (17.2 mg) and are from post‑hoc subgroup analyses.